Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From GSK plc

Finance Watch: Rivus Raises $132m In Series B Cash To Fund Obesity Drug Trials

VC funding slowed recently, but public company financings kept up a brisk pace with follow-on public offerings for Allakos and Alpine, private placements for Ventyx and Syros, and Albireo’s royalty deal. In restructuring updates, Biogen raised $592m in a real estate deal and Acerus is assessing options.

Financing Growth

Deal Watch: GSK Gets Rights To Spero’s Phase III Antibiotic

GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.

Deal Watch Business Strategies

Merck KGaA Joins Race To Develop Next-Gen PARP Inhibitors

PARP inhibitors have had great success in treating a number of cancers but the German major has placed a $65m bet that Nerviano's selective PARP1 approach could produce a safer and more efficacious option.

Cancer Deals

US FDA Panel To Weigh Whether Copiktra’s Benefit-Risk Profile In Hematologic Cancers Has Changed

Adverse trend in overall survival, tolerability concerns, and uncertainty regarding the dose suggest the PI3K inhibitor's benefit-risk profile in its current indications is unfavorable, FDA says. Secura Bio asserts OS data are confounded and safety issues are the same as at initial approval.

Advisory Committees Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Other Names / Subsidiaries
    • ABR Development
    • Affinivax, Inc.
    • Cellzome
    • Corixa Corporation
    • Fountain Acquisition Corporation
    • Genelabs Technologies, Inc.
    • GlycoVaxyn AG
    • Human Genome Sciences, Inc.
    • GlaxoSmithKline plc
    • ID Biomedical Corporation
    • Okairos AG
    • PRAECIS Pharmaceuticals, Inc.
    • Reliant Pharmaceuticals
    • Sierra Oncology, Inc.
    • Sirtris Pharmaceuticals
    • Sitari Pharmaceuticals, Inc.
    • SmithKline Beecham
    • Stiefel Laboratories, Inc.
    • Tesaro, Inc.
    • ViiV Healthcare
UsernamePublicRestriction

Register